

ASX ANNOUNCEMENT**13 August 2021****Emyria and Cann Group mutually agree
to terminate collaboration arrangements**

13 August 2021 - Emyria Limited (ASX: EMD) (**Emyria**) and Cann Group Limited (ASX: CAN) (**Cann**) today announced that both companies have mutually agreed to terminate a collaboration agreement relating to the planned registration of a Schedule 3 (**S3**) medicine CBD product.

The collaboration was announced in an ASX release on 29 March 2021 and envisaged that both companies would co-operate to progress a Schedule 3 over-the-counter cannabidiol (**CBD**) medicine with Australia's Therapeutic Goods Administration (**TGA**) by utilising Emyria's EMD-003 drug development program and Cann's proprietary Gelpell microsphere technology.

Following a detailed review, both companies have agreed to formally terminate those arrangements and mutually release each other from the obligations of the collaboration agreement.

Both Emyria and Cann plan to independently pursue registration programs for an S3 CBD product.

This announcement has been approved and authorised for release by the Board of Emyria Limited and the Board of Cann Group Limited.

For all enquiries to Emyria please contact:

Dr. Michael Winlo
Managing Director
(08) 6559 2800
mwinlo@emyria.com

Lexi O'Halloran
Media/Investor Relations
+ 61 (0) 404 577 076
lexi@janemorganmanagement.com.au

Andrew Williams
Media Relations
+61 (0) 412 614 125
andrew@profilemedia.com.au

For all media enquiries to Cann please contact:

Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

For all other information regarding Cann Group please contact:

Peter Crock
CEO
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

Clive Fanning
Head of Investor Relations
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

About Emyria (www.emyria.com)

Emyria Limited is a data-backed, drug development company. Emyria's Treatments target unmet needs and are focused on obtaining approval from major global regulators. Emyria's drug development programs are informed by insights generated from extensive analysis of Emyria Data - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria's independent clinical services. (Emerald Clinics - www.emeraldclinics.com.au). Emyria Data provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs.

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. Cann also owns Satipharm, a Europe-based business exclusively licensed to manufacture, develop and market the proprietary Gelpell delivery system for cannabinoids. Cann has established research and cultivation facilities in Melbourne and is developing a state-of-the-art cultivation and manufacturing facility near Mildura, Victoria. Cann Group has established a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products.

Learn more at: www.canngrouponlimited.com | www.satipharm.com